首页> 美国卫生研究院文献>Annals of Oncology >N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial

【2h】

N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial

机译：N0539氟维司群和贝伐单抗在先前用芳香酶抑制剂治疗的转移性乳腺癌患者中的II期临床试验：北中部癌症治疗组（现为Alliance）试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundBased on preclinical studies, the vascular endothelial pathway is an important mechanism for estrogen receptor resistance. We conducted a phase II study of fulvestrant and bevacizumab in patients with aromatase inhibitor pretreated metastatic breast cancer.

机译：背景基于临床前研究，血管内皮途径是雌激素受体抵抗的重要机制。我们对芳香酶抑制剂预处理的转移性乳腺癌患者进行了氟维司群和贝伐单抗的II期研究。

著录项

期刊名称 Annals of Oncology
作者
W. W. Tan; A. C. Dueck; P. Flynn; P. Steen; D. Anderson; K. Rowland; D. Northfelt; E. A. Perez;
展开▼
作者单位

展开▼
年(卷),期 -1(24),10
年度 -1
页码 2548–2554
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词
antiangiogenesis agent aromatase inhibitor resistance bevacizumab estrogen receptor antagonist fulvestrant metastatic breast cancer;

机译：抗血管生成剂;抗芳香化酶抑制剂;贝伐单抗;雌激素受体拮抗剂;氟维司群;转移性乳腺癌;

相似文献

外文文献
中文文献
专利

1. N0539 phase ii trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: A north central cancer treatment group (now alliance) trial [J] . TanW.W., DueckA.C., FlynnP., Annals of oncology: official journal of the European Society for Medical Oncology . 2013 ,第10期

机译：N0539氟维司群和贝伐单抗在先前用芳香酶抑制剂治疗的转移性乳腺癌患者中的II期临床试验：北中部癌症治疗组（现为联盟）试验
2. N0539 phase ii trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: A north central cancer treatment group (now alliance) trial [J] . TanW.W., DueckA.C., FlynnP., Annals of oncology: official journal of the European Society for Medical Oncology . 2013 ,第10期

机译：N0539期二期试验在先前用芳香酶抑制剂治疗的转移性乳腺癌患者中的血露雌蕊和贝伐单抗：北中央癌症治疗组（现在联盟）试验
3. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance) [J] . Hubbard Joleen M., Mahoney Michelle R., Loui William S., Targeted oncology . 2017 ,第2期

机译：I / II阶段I / II随机试验Sorafenib和Bevacizumab作为局部晚期或转移性肝细胞癌患者的一线治疗：北中央癌症治疗组试验N0745（联盟）
4. Aromatase Inhibitors in Prevention - Data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial and the Design of IBIS-II (the Second International Breast Cancer Intervention Study) [C] . Jack Cuzick International Society of Cancer Chemoprevention . 2003

机译：预防芳族酶抑制剂 - 来自ATAC（ARIMIDEX，Tamoxifen单独或组合或组合的数据）的数据和IBIS-II的设计（第二次国际乳腺癌干预研究）
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance) [O] . Joleen M. Hubbard, Michelle R. Mahoney, William S. Loui, -1

机译：索拉非尼和贝伐单抗的I / II期随机试验作为局部晚期或转移性肝细胞癌患者的一线治疗：北中部癌症治疗组试验N0745（联盟）
7. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer [O] . Perez, E. A., Hillman, D. W., Dentchev, T., 2009

机译：北部中部癌症治疗组（NCCTG）N0432：多西他赛联合卡培他滨和贝伐单抗作为转移性乳腺癌患者的一线化疗的II期临床试验

N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial

摘要

著录项

相似文献

相关主题

期刊订阅